Sol-Gel Technologies (SLGL) fell ~10% in the premarket on Wednesday after the dermatological drug developer announced that ...

Sol-Gel Technologies ends development of SGT-210 in Darier disease after Phase 1b data show no efficacy versus vehicle.

Fintel reports that on December 22, 2025, HC Wainwright & Co. reiterated coverage of Sol-Gel Technologies (NasdaqCM:SLGL) with a Buy recommendation. Analyst Price Forecast Suggests 20.97% Upside As of ...

NESS ZIONA, Israel, May 01, 2025 (GLOBE NEWSWIRE) -- Sol-Gel Technologies Ltd. (the “Company”) (NASDAQ: SLGL), a clinical-stage dermatology company, today announced a reverse share split (the “Reverse ...

NESS ZIONA, Israel, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering treatments for patients with rare and severe skin conditions, today ...

SLGL is trading near the top of its 52-week range and above its 200-day simple moving average. Price change The price of SLGL shares has decreased $0.59 since the market last closed. This is a 1.38% ...

Sol-gel manufacturing can be used to create various high-performance solids including glasses and ceramics. In the field of glass production, sol-gel techniques are a reliable low-temperature ...

NESS ZIONA, Israel, May 16, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering treatments for patients with severe skin conditions, conducting a ...

NESS ZIONA, Israel & LAUSANNE, Switzerland--(BUSINESS WIRE)--Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatology company, and Galderma, the world’s largest independent dermatology ...